Skip to main content
Top
Published in: Diabetologia 9/2009

01-09-2009 | Short Communication

Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes

Authors: P. Wiesli, P. Krayenbühl, H. Uthoff, B. Seifert, C. Schmid

Published in: Diabetologia | Issue 9/2009

Login to get access

Abstract

Aims/hypothesis

The aim of this prospective trial was to compare the effect of different long-acting insulin preparations injected at bedtime on glucose concentrations in patients with type 2 diabetes omitting breakfast and lunch the next day.

Methods

Twenty patients (ten women) with type 2 diabetes who were on an intensified insulin therapy participated. Mean (±SD) age was 63 ± 10 years, diabetes duration 18 ± 9 years, BMI 32.5 ± 5 kg/m2, and HbA1c 7.3 ± 0.7%. Patients received neutral protamine Hagedorn (NPH) insulin, insulin detemir or insulin glargine for at least 2 months; doses were adjusted to achieve morning blood glucose levels of <7 mmol/l. At the end of the respective treatment period, the long-acting insulin was injected at bedtime (at 22:45 hours) as usual but patients refrained from breakfast and lunch the next day; glucose was measured by a continuous glucose monitoring system (CGMS).

Results

Comparable glucose target ranges were reached at midnight (5.8 to 6.1 mmol/l) and at 07:00 hours (6.7 to 6.9 mmol/l) with all three insulin preparations, using mean doses of 29 ± 10 U (NPH insulin), 33 ± 13 U (insulin detemir), and 32 ± 12 U (insulin glargine). Glucose levels between midnight and 07:00 hours were not significantly different for the three insulin preparations. Symptomatic hypoglycaemia did not occur from 08:00 to 16:00 hours; glucose concentrations during this time were slightly lower with NPH insulin than with insulin detemir (p = 0.012) and insulin glargine (p = 0.049).

Conclusions/interpretation

Following bedtime injection of NPH insulin or of the analogues insulin detemir or insulin glargine, fasting glucose <7 mmol/l was achieved in the morning, without subsequent hypoglycaemia when participants continued to fast during the day.
Literature
1.
go back to reference Heise T, Nosek L, Rønn B et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620PubMedCrossRef Heise T, Nosek L, Rønn B et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620PubMedCrossRef
2.
go back to reference Plank J, Bodenlenz M, Sinner F et al (2005) A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107–1112PubMedCrossRef Plank J, Bodenlenz M, Sinner F et al (2005) A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107–1112PubMedCrossRef
3.
go back to reference Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148CrossRef Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148CrossRef
4.
go back to reference Swinnen S, Holleman F, DeVries J (2008) The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 51:1790–1795PubMedCrossRef Swinnen S, Holleman F, DeVries J (2008) The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. Diabetologia 51:1790–1795PubMedCrossRef
5.
6.
go back to reference Trümper B, Reschke K, Molling J (1995) Circadian variation of insulin requirement in insulin dependent diabetes mellitus the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia. Horm Metab Res 27:141–147PubMedCrossRef Trümper B, Reschke K, Molling J (1995) Circadian variation of insulin requirement in insulin dependent diabetes mellitus the relationship between circadian change in insulin demand and diurnal patterns of growth hormone, cortisol and glucagon during euglycemia. Horm Metab Res 27:141–147PubMedCrossRef
7.
go back to reference Shapiro E, Polonsky K, Copinschi G et al (1991) Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 72:444–454PubMedCrossRef Shapiro E, Polonsky K, Copinschi G et al (1991) Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 72:444–454PubMedCrossRef
8.
go back to reference Wiesli P, Lehmann R, Krayenbuehl P, Schmid C, Spinas G (2006) Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 114:539–543PubMedCrossRef Wiesli P, Lehmann R, Krayenbuehl P, Schmid C, Spinas G (2006) Assessment of basal insulin requirement using fasting tests in insulin-treated patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 114:539–543PubMedCrossRef
9.
go back to reference Cockcroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft D, Gault M (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
10.
go back to reference Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMedCrossRef Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000) Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649PubMedCrossRef
Metadata
Title
Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes
Authors
P. Wiesli
P. Krayenbühl
H. Uthoff
B. Seifert
C. Schmid
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 9/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1439-z

Other articles of this Issue 9/2009

Diabetologia 9/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.